These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 25092217)
1. Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer. Rinck-Junior JA; Oliveira C; Lourenço GJ; Sagarra RA; Derchain SF; Segalla JG; Lima CS J Cancer Res Clin Oncol; 2015 Jan; 141(1):69-73. PubMed ID: 25092217 [TBL] [Abstract][Full Text] [Related]
2. Clinical relationships between the rs2212020 and rs189897 polymorphisms of the Liu J; Liu T; Liang L; He J; Zhang M; Ge Y; Liao S; Zhou Y; Zhang K J Genet; 2019 Mar; 98():. PubMed ID: 30945681 [TBL] [Abstract][Full Text] [Related]
3. The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Heubner M; Wimberger P; Riemann K; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W Oncol Res; 2010; 18(7):343-7. PubMed ID: 20377136 [TBL] [Abstract][Full Text] [Related]
4. The androgen receptor cytosine-adenine-guanine repeat length contributes to the development of epithelial ovarian cancer. Meng X; Lu P; Chu Z; Fan Q Oncotarget; 2016 Jan; 7(2):2105-12. PubMed ID: 26556855 [TBL] [Abstract][Full Text] [Related]
5. The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer. Heubner M; Wimberger P; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W Anticancer Res; 2009 Aug; 29(8):3449-52. PubMed ID: 19661372 [TBL] [Abstract][Full Text] [Related]
6. Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. Fridley BL; Jenkins GD; Tsai YY; Song H; Bolton KL; Fenstermacher D; Tyrer J; Ramus SJ; Cunningham JM; Vierkant RA; Chen Z; Chen YA; Iversen E; Menon U; Gentry-Maharaj A; Schildkraut J; Sutphen R; Gayther SA; Hartmann LC; Pharoah PD; Sellers TA; Goode EL Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):529-36. PubMed ID: 22302016 [TBL] [Abstract][Full Text] [Related]
7. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D; Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147 [TBL] [Abstract][Full Text] [Related]
8. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy. Liblab S; Vusuratana A; Areepium N Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417 [TBL] [Abstract][Full Text] [Related]
10. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma. S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147 [TBL] [Abstract][Full Text] [Related]
11. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
12. [Single nucleotide polymorphisms in cell cycle regulator p21 and p27 genes are associated with susceptibility to epithelial ovarian cancer]. Jin X; Kang S; Wang N; Xing YP; Li Y Zhonghua Fu Chan Ke Za Zhi; 2008 Mar; 43(3):209-12. PubMed ID: 18788572 [TBL] [Abstract][Full Text] [Related]
13. p16(CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China. Yan L; Na W; Shan K; Xiao-Wei M; Wei G; Shu-Cheng C Int J Gynecol Cancer; 2008; 18(1):30-5. PubMed ID: 17466040 [TBL] [Abstract][Full Text] [Related]
15. Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival. O'Mara TA; Nagle CM; Batra J; Kedda MA; Clements JA; Spurdle AB Twin Res Hum Genet; 2011 Aug; 14(4):323-7. PubMed ID: 21787114 [TBL] [Abstract][Full Text] [Related]
16. Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers. Konac E; Onen HI; Metindir J; Alp E; Biri AA; Ekmekci A DNA Cell Biol; 2007 Jul; 26(7):453-63. PubMed ID: 17630849 [TBL] [Abstract][Full Text] [Related]
17. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793 [TBL] [Abstract][Full Text] [Related]
18. Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries. González-Palomares B; Coronado Martín PJ; Maestro de Las Casas ML; Veganzones de Castro S; Rafael Fernández S; Vidaurreta Lázaro M; De la Orden García V; Vidart Aragon JA Int J Gynecol Cancer; 2017 Jul; 27(6):1088-1095. PubMed ID: 28574932 [TBL] [Abstract][Full Text] [Related]
19. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas. Gyftaki R; Liacos C; Politi E; Liontos M; Saltiki K; Papageorgiou T; Thomakos N; Haidopoulos D; Rodolakis A; Alevizaki M; Bamias A; Dimopoulos A Int J Gynecol Cancer; 2014 Jun; 24(5):851-6. PubMed ID: 24844218 [TBL] [Abstract][Full Text] [Related]